Skip Navigation

Cardiovascular Research 2003 57(1):225-231; doi:10.1016/S0008-6363(02)00659-4
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ahmed, Z.
Right arrow Articles by Connelly, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahmed, Z.
Right arrow Articles by Connelly, P. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine

Zakaria Ahmedh, Saeid Babaeic, Graham F. Maguirea, Dragomir Draganovg, Arnis Kuksisd, Bert N. La Dug and Philip W. Connellya,b,e,f,*

aJ. Alick Little Lipid Research Laboratory, St. Michael's Hospital, Room 1004 WA, 38 Shuter Street, Toronto, Ont., Canada M5B 1A6
bDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ont., Canada
cTerrence Donnelly Vascular Biology Laboratory, St. Michael's Hospital, Toronto, Ont., Canada
dBanting and Best Department of Medical Research, University of Toronto, Toronto, Ont., Canada
eDepartment of Biochemistry, University of Toronto, Toronto, Ont., Canada
fDepartment of Medicine, University of Toronto, Toronto, Ont., Canada
gDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA
hDepartment of Pathology and Laboratory Medicine, University of Louisville Medical Center, Louisville, KY 40202, USA

* Corresponding author. Present address: J. Alick Little Lipid Research Laboratory, St. Michael's Hospital, Room 1004 WA, 38 Shuter Street, Toronto, Ont., Canada M5B 1A6. Tel.: +1-416-864-6023; fax: +1-416-864-5870. connellyp{at}smh.toronto.on.ca

Objective: High-density lipoprotein (HDL) is postulated to protect against the development of atherosclerosis, in part, by inhibiting the oxidation of low density lipoprotein (LDL) in the sub-endothelial space and thus inhibiting activation of the endothelium. The HDL-associated enzyme, paraoxonase-1, is proposed to be a major protective factor. However, HDL is also prone to oxidation when exposed to peroxynitrite and may therefore, once oxidized, have properties similar to oxidized LDL. Methods and results: We exposed human HDL to the peroxynitrite donor 3-morpholinosydnonimine and incubated oxidized HDL with human umbilical vein endothelial cells (HUVECs). Oxidized HDL increased monocyte binding (P<0.001) and enhanced chemotaxis (P<0.001). The major oxidized phospholipids were 1-palmitoyl (stearoyl)-2-[9-oxo]nanoyl(azelaoyl)-sn-glycero-phosphocholine, derived from linoleate-containing phosphatidylcholines, and 1-palmitoyl(stearoyl)-2-[5-oxo]valeroyl(glutaroyl)-sn-glycero-phosphocholine, derived from arachidonate-containing phosphatidylcholines. Incubation of HUVECs with synthetically prepared 1-palmitoyl-2-[9-oxo]nanoyl(azelaoyl)-sn-glycero-phosphocholine, or 1-palmitoyl-2-[5-oxo]valeroyl(glutaroyl)-sn-glycero-phosphocholine increased binding of monocytes (P<0.001) and chemotaxis (P<0.001). Purified paraoxonase-1 reduced monocyte adhesion and chemotaxis (P<0.001). Conclusions: (i) HDL can be a source of oxidatively-derived bioactive phospholipids; (ii) the fragmented phospholipids with a 9-carbon aldehyde or acid are as effective as a 5-carbon aldehyde or acid at inducing monocyte adhesion and chemotaxis; and (iii) paraoxonase-1 is effective at reducing the activity of these phospholipid oxidation products.

KEYWORDS apoA-I, apolipoprotein A-I; HDL, high density lipoproteins; HPF, high powered field; HUVECs, human umbilical vein endothelial cells; LC–ESI-MS, liquid chromatography–electrospray ionization-mass spectrometry; LDL, low density lipoproteins; PAPC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; PAzPC, 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine; PC, phosphatidylcholine; PGPC, 1-palmitoyl-2-(glutaroyl)-sn-glycero-phosphocholine; PLPC, 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine; PON-1, paraoxonase-1; PONPC, 1-palmitoyl-2-(9-oxo)nonanoyl-sn-glycero-3-phosphocholine; POVPC, 1-palmitoyl-2-[5-oxo]valeroyl-sn-glycero-phosphocholine; SGPC, 1-stearoyl-2-(glutaroyl)-sn-glycero-phosphocholine; SIN-1, 3-morpholinosydnonimine; SOVPC, 1-stearoyl-2-[5-oxo]valeroyl-sn-glycero-phosphocholine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.